Neil Kumar, BridgeBio CEO (JT MacMillan Photography for Endpoints News)
August 21, 2024 09:43 AM EDTUpdated 12:59 PM
Financing
Startups
Deals

Bridge­Bio forms an­oth­er off­shoot with $300M in com­mit­ments

Kyle LaHucik

Senior Reporter

Bridge­Bio is again of­fload­ing pieces of its pipeline as it stares down a No­vem­ber drug ap­proval de­ci­sion that could spark com­pe­ti­tion with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

Sanofi buys in­to ra­dio­phar­ma­ceu­ti­cal field with $110M up­front, go­ing af­ter space held by No­var­tis

A new start­up wants to fight can­cer with 'off-the-shelf' gene ther­a­py, se­cur­ing $26M seed round

Sofinno­va’s Jim Healy on ‘more ra­tio­nal mar­ket’ as four biotech star­tups near their IPOs

J&J ex­pands Trem­fya in­to IBD with new FDA ap­proval

Au­ra's in­frared light-ac­ti­vat­ed drug stops tu­mor growth and pre­serves vi­sion in eight eye can­cer pa­tients

A service from the Financial Times